Visiongain Publishes Automated Cannabis Testing Market Report to 2031
22 February 2021
Visiongain has published a new report on Automated Cannabis Testing Market Report to 2031. According to the Visiongain analysis, the global Automated Cannabis Testing market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global Automated Cannabis Testing market is segmented by type (Terpene profiling, Residual Solvents, Heavy Metals, Pesticide Screening, Potency testing, Microbial Testing, Genetic Testing), By Product & Software (Analytical Instruments(Chromatography Instruments, Gas Chromatography, Liquid Chromatography, Others, Spectroscopy Instruments, Mass Spectroscopy, Atomic Spectroscopy, Other), Consumables (Chromatography Column, Supplies and Accessories, Standards and CRMS, Sample Preparation Products), Software), By End User (Testing Laboratories, Research Institute, Others). Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed Profiles of Leading Automated Cannabis Testing Companies. PLUS COVID-19 Recovery Scenarios.
Global Automated Cannabis Testing Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing adoption of laboratory information management system (LIMS) in Cannabis Testing Laboratories and Rising Number of Cannabis Testing Laboratories are some of the factors driving the growth of Automated Cannabis Testing market.
COVID-19 Impact on the Global Automated Cannabis Testing Market
The COVID-19 is a new virulent disease, growing transmission and fatal outcome in the global population. The use of cannabidiol (CBD) in medical purposes is safe & effective to treat medical condition. The CBD has anti-inflammatory properties, and have ability to reduce pain & anxiety. Additionally, the combination of other cannabinoids and terpenes, are significant in clinical intervention, and have potential to treat symptoms of a virus such as COVID-19.
Rising legalization for therapeutic & medical use.
The use of Cannabis for Therapeutic Purposes (CTP) has recently become legal in various countries. However, the legalization in various places enables in easy availability, and change in cannabis perceptions. The increasing clinical evidence-base for use of cannabis therapeutics associated social and political pressures to modify regulatory frameworks for legalization on the use of cannabis. The marijuana plant Cannabis sativa and derivatives, cannabinoids, has significant potential therapy for inflammatory bowel disease (IBD). The Cannabidiol is one of the naturally occurring cannabinoids, which is found in cannabis. The cannabinoids are efficient to treat epilepsy in various clinical trials. The Epidiolex oral solution is one pure CBD product, received US FDA approval treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Increasing adoption of laboratory information management system (LIMS) in Cannabis Testing Laboratories
The Laboratory Information Management System (LIMS) is a software tool enables in efficient data management and laboratory operation. It enables to provide regulatory compliance and offers accurate and speedy outcomes. The cannabis testing workflow provides wide range of testing services which includes terpene profiling, screening pesticide level, heavy metal, and residual solvent testing.
Increasing recommendation to encourage improvisation in cannabis research.
The U.S. Department of Health and Human Services, including the National Institutes of Health and the Centers for Disease Control and Prevention, must collaborate to jointly invest in R&D, & ensure the implementation of guidelines for production of high-quality cannabis research. The research programs must enhance the benefits linked with acute & chronic use and reduce harm associated with cannabis & cannabinoids.
Agilent Technologies, Inc., Shimadzu Corporation, MCS, Inc., Restek Corporation, A&L Canada Laboratories Inc., Marrone Bio Innovations, Emerald Scientific LLC, PerkinElmer, Inc., Millipore Sigma, AB SCIEX LLC are some of the key players contributing to the growth of the global Automated Cannabis Testing market. The market players are adopting new strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
For instance, in August 2020, A&L Canada Laboratories Inc. announced the addition of Hop Latent Viroid (HLVd) testing to their Cannabis Disease Diagnostics Services. The company is providing Plant Disease Diagnostics (PDD), for horticultural and greenhouse crops. The company offers inclusive pest diagnosis and services to detect plant pathogens such as fungi, bacteria, viruses, and nematodes, associated with plant tissues, soils, composts and water.
In October 2020, PerkinElmer, Inc. launched a fully automated liquid handling sample preparation and LC/MS/MS analysis workflow for pesticide residue testing of cannabis and hemp flower samples. It offers cannabis-optimized reagents, sample prep consumables, proprietary cannabis SOPs and cloud-based tracking and reporting software.
In August 2020, Marrone Bio Innovations, Inc. an international leader in sustainable bioprotection and plant health solutions, entered in an agreement with Vive Crop Protection. The collaboration enables the company to combine biological with Allosperse Delivery System. The first product to come from this joint effort will The AZterknot FC will be company’s joint product, a fungicide for broad crop use marketed by Vive Crop Protection.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Visiongain Publishes Allergy Immunotherapy Market Report 2023-2033
The global Allergy Immunotherapy market is projected to grow at a CAGR of 7.6% by 2033
31 May 2023
Visiongain Publishes AI-based Clinical Trial Solution Providers Market Report 2023-2033
The global AI-based Clinical Trial Solution Providers market was valued at US$1,232.0 million in 2022 and is projected to grow at a CAGR of 23.3% during the forecast period 2023-2033.
26 May 2023
Visiongain Publishes Vaccine Contract Manufacturing Market Report 2023-2033
The global Vaccine Contract Manufacturing Market is projected to grow at a CAGR of 13.2% by 2033
24 May 2023
Visiongain Publishes Cell & Gene Therapy Cold Chain Logistics Market Report 2023-2033
The global Cell & Gene Therapy Cold Chain Logistics market is projected to grow at a CAGR of 15% by 2033